Agarwal Vineet
Known title: Chief Financial OfficerCIK: 0001997973
Associated companies
Transaction History
| KRRO | ▲ Buy | Option Exercise | 800 | $9K | 11/11/2024 | View on chart |
| KRRO | ▼ Sell | Open Market | 800 | $56K | 11/11/2024 | View on chart |
| KRRO | ▲ Buy | Option Exercise | 9,263 | $108K | 10/17/2024 | View on chart |
| KRRO | ▲ Buy | Option Exercise | 953 | $14K | 10/17/2024 | View on chart |
| KRRO | ▼ Sell | Open Market | 2,023 | $145K | 10/17/2024 | View on chart |
| KRRO | ▼ Sell | Open Market | 260 | $20K | 10/17/2024 | View on chart |
| KRRO | ▼ Sell | Open Market | 457 | $36K | 10/17/2024 | View on chart |
| KRRO | ▼ Sell | Open Market | 1,815 | $145K | 10/17/2024 | View on chart |
| KRRO | ▼ Sell | Open Market | 4,961 | $399K | 10/17/2024 | View on chart |
| KRRO | ▼ Sell | Open Market | 317 | $26K | 10/17/2024 | View on chart |
| KRRO | ▼ Sell | Open Market | 25 | $2K | 10/17/2024 | View on chart |
| KRRO | ▼ Sell | Open Market | 115 | $9K | 10/17/2024 | View on chart |
| KRRO | ▼ Sell | Open Market | 56 | $4K | 10/17/2024 | View on chart |
| KRRO | ▼ Sell | Open Market | 164 | $12K | 10/17/2024 | View on chart |
| KRRO | ▼ Sell | Open Market | 23 | $2K | 10/17/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Korro Bio Begins Phase 1/2 Trial for KRRO-121
Korrr Bio has begun dosing the first cohort of its Phase 1/2 study for KRRO-121, a therapy aimed at treating hyperammonemia in patients with urea cycle disorders. The initiation of this trial marks a significant milestone in the drug’s development timeline. Analysts continue to hold a $15 price target, reflecting confidence in the program. Current technical data shows the stock trading near its 52‑week low with an RSI of 39.7.
Korro Bio Begins Phase 1/2 Trial for KRRO-121. Korrr Bio has begun dosing the first cohort of its Phase 1/2 study for KRRO-121, a therapy aimed at treating hyperammonemia in patients with urea cycle disorders. The initiation of this trial marks a significant milestone in the drug’s development timeline. Analysts continue to hold a $15 price target, reflecting confidence in the program. Current technical data shows the stock trading near its 52‑week low with an RSI of 39.7.